Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ALK G1202R

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4